Neurosense Therapeutics Ltd Stock Price, News & Analysis

NeuroSense Therapeutics (Nasdaq: NRSN) announced the enrollment of the first patient in its Phase IIb PARADIGM trial for PrimeC, aimed at treating amyotrophic lateral sclerosis (ALS). The trial, which will include 69 participants from Israel, Italy, and the U.S., is designed to assess ALS-related biomarkers and clinical efficacy. PrimeC, a combination of ciprofloxacin and celecoxib, has FDA and EMA Orphan Drug Designation. Previous Phase IIa results showed significant efficacy, including reduced respiratory deterioration. Top-line results from PARADIGM are expected by Q2 2023.

NeuroSense Therapeutics (NASDAQ: NRSN) reported Q1 2022 financial results, revealing a cash position of $13.74 million, up from $11.06 million in Q4 2021. The net loss increased to $2.71 million from $2.12 million in Q1 2021, primarily due to heightened general and administrative expenses. Notably, the company initiated biomarker studies for ALS and Alzheimer's, received FDA clearance for its IND application for PrimeC, and commenced a pharmacokinetic study. Looking ahead, a Phase IIb ALS clinical trial is set to begin in Q2 2022, with results anticipated in Q3.

NeuroSense Therapeutics (Nasdaq: NRSN) announces that Dr. Ferenc Tracik will present at the ALS Drug Development Summit on May 26, 2022, in Boston. The focus will be on the company's Phase IIb study, PARADIGM, that aims to evaluate the combination therapy PrimeC in treating ALS. The presentation will cover the design and findings of earlier trials, emphasizing the significance of ALS biomarkers for regulatory approval. NeuroSense is progressing towards a Phase IIb trial scheduled for Q2 2022, targeting ALS disease progression and aiming to enhance patient quality of life.

NeuroSense Therapeutics has initiated a pharmacokinetic study for its lead drug candidate PrimeC, aimed at treating amyotrophic lateral sclerosis (ALS). This study, conducted under an FDA-cleared protocol, enrolled the first healthy volunteer as of April 11, 2022. PrimeC combines the FDA-approved drugs ciprofloxacin and celecoxib to target mechanisms of ALS. The company anticipates reporting results by Q3 2022, which will inform a pivotal Phase III trial. PrimeC has received Orphan Drug Designation from both the FDA and EMA.

NeuroSense Therapeutics announced the grant of a key patent in Canada for its ALS drug, PrimeC, which combines FDA-approved drugs ciprofloxacin and celecoxib. The patent is valid through 2038 and complements similar patents issued in the U.S. and Australia. The company plans to initiate a Phase IIb trial in Q2 2022 to evaluate PrimeC's efficacy after a successful Phase IIa study. Concurrently, NeuroSense is collaborating with Massachusetts General Hospital on ALS biomarkers, with results expected in the same timeframe.

NeuroSense Therapeutics (Nasdaq: NRSN) announced new developments in its clinical program for lead drug candidate PrimeC targeting ALS. Two clinical studies are set to begin in Q2 2022, including a pharmacokinetic study and a Phase IIb multinational study, both aiming to enhance therapeutic effectiveness. The company is also expanding its intellectual property, with a key patent granted in the US and Australia. Upcoming data from studies on CogniC and StabiliC are anticipated in 2022, marking crucial milestones for NeuroSense's therapeutic pipeline.

NeuroSense Therapeutics Ltd. (NRSN) announced it has raised approximately $4 million through the exercise of warrants priced at $6 per share. This funding extends its cash runway through Q3 2023, coinciding with the planned Phase IIb study for PrimeC, targeting amyotrophic lateral sclerosis (ALS). PrimeC has previously met safety and efficacy endpoints in a Phase IIa study and has received Orphan Drug Designation from the FDA and EMA. ALS poses a significant healthcare burden affecting over 5,000 new patients annually in the U.S.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced FDA clearance to initiate a pharmacokinetic study of PrimeC, an oral formulation for ALS. PrimeC combines ciprofloxacin and celecoxib, targeting mechanisms of motor neuron degeneration. Having completed a successful Phase IIa study, NeuroSense is set to start a Phase IIb study in Q2 2022. The pharmacokinetic study will assess PrimeC's bioavailability in healthy subjects. The ALS treatment market is valued at $3 billion, with significant unmet needs identified, as ALS diagnoses are expected to increase by 24% by 2040.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced its participation in the 2022 Virtual Growth Conference on March 28-30, 2022. CEO Alon Ben-Noon will present during a fireside chat titled "NeuroSense – Novel Approach to Tackle ALS on Multiple Fronts" on March 30 at 09:30 AM EDT. The conference will feature various sectors, including biotech and healthcare, and will be hosted by Maxim Group LLC. NeuroSense focuses on developing treatments for neurodegenerative diseases, with promising results from its Phase 2a clinical study of PrimeC for ALS.